Abdullah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abdullah has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Humza Saeed
Department of Internal Medicine, Rawalpindi Medical University
3 shared publications- Humza Saeed
Department of internal medicine Rawalpindi Medical University Rawalpindi Pakistan
3 shared publications - Abdul Rafae Faisal
Department of Medicine, CMH Multan Institute of Medical Sciences, Multan, Pakistan
2 shared publications Ajeet Singh
Department of Internal Medicine, Dow University of Health Sciences
2 shared publications- Ali Shan Hafeez
CMH Multan Institute of Medical Sciences, Multan, Pakistan
2 shared publications Aman Goyal
Affiliations Department of Internal Medicine, Seth GS Medical College and KEM Hospital, Mumbai, India
2 shared publications
Latest Publications
- Open Access
Electronic Glycemic Management Systems Versus Conventional Insulin Infusion Protocols in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Non-Randomized Studies
Background and Objectives: Electronic glycemic management systems (eGMSs) are increasingly used to guide intravenous insulin infusion for hospitalized patients with diabetic ketoacidosis (DKA), but available comparative evidence remains non-randomized and clinically heterogeneous and includes multiple algorithmically distinct platforms. Methods and Materials: We conducted a systematic review and meta-analysis in accordance with PRISMA guidance and a prospectively registered protocol (PROSPERO: 2025 CRD420251019614). Seven non-randomized studies comprising 3874 hospitalized patients were included; six studies contributed data to the primary meta-analysis of time to DKA resolution. The primary outcome was time to DKA resolution. Secondary outcomes included ICU length of stay (LOS), hospital LOS, duration of insulin infusion, and hypoglycemia (mild and severe). Random-effects models were applied. Results: Six studies contributed to the primary meta-analysis of time to DKA resolution; across the review, seven studies included 3874 patients. The pooled analysis showed no statistically significant difference between groups (SMD −0.04, 95% CI −0.22 to 0.14; I2 = 74.8%). Recorded hypoglycemia was lower among patients managed with eGMS; however, these estimates should be interpreted cautiously because of heterogeneity, serious-to-critical risk of bias, and potential differences in glucose-monitoring and documentation practices. ICU and hospital LOSs and duration of insulin infusion showed no statistically significant differences overall, with heterogeneity across studies. Conclusions: In available non-randomized evidence, eGMS-guided insulin infusion was not associated with a clear difference in time to DKA resolution, ICU length of stay, hospital length of stay, or insulin infusion duration compared with conventional protocols. Lower recorded hypoglycemia was observed with eGMSs, but this finding should be considered hypothesis-generating because of serious-to-critical risk of bias, residual confounding, substantial heterogeneity, and possible detection bias. High-quality randomized trials or target trial emulation studies are needed before recommending widespread adoption, as certainty of evidence was very low across all outcomes.
Open AccessElectronic Glycemic Management Systems Versus Conventional Insulin Infusion Protocols in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis of Non-Randomized Studies
Background and Objectives: Electronic glycemic management systems (eGMSs) are increasingly used to guide intravenous insulin infusion for hospitalized patients with diabetic ketoacidosis (DKA), but available comparative evidence remains non-randomized and clinically heterogeneous and includes multiple algorithmically distinct platforms. Methods and Materials: We conducted a systematic review and meta-analysis in accordance with PRISMA guidance and a prospectively registered protocol (PROSPERO: 2025 CRD420251019614). Seven non-randomized studies comprising 3874 hospitalized patients were included; six studies contributed data to the primary meta-analysis of time to DKA resolution. The primary outcome was time to DKA resolution. Secondary outcomes included ICU length of stay (LOS), hospital LOS, duration of insulin infusion, and hypoglycemia (mild and severe). Random-effects models were applied. Results: Six studies contributed to the primary meta-analysis of time to DKA resolution; across the review, seven studies included 3874 patients. The pooled analysis showed no statistically significant difference between groups (SMD −0.04, 95% CI −0.22 to 0.14; I2 = 74.8%). Recorded hypoglycemia was lower among patients managed with eGMS; however, these estimates should be interpreted cautiously because of heterogeneity, serious-to-critical risk of bias, and potential differences in glucose-monitoring and documentation practices. ICU and hospital LOSs and duration of insulin infusion showed no statistically significant differences overall, with heterogeneity across studies. Conclusions: In available non-randomized evidence, eGMS-guided insulin infusion was not associated with a clear difference in time to DKA resolution, ICU length of stay, hospital length of stay, or insulin infusion duration compared with conventional protocols. Lower recorded hypoglycemia was observed with eGMSs, but this finding should be considered hypothesis-generating because of serious-to-critical risk of bias, residual confounding, substantial heterogeneity, and possible detection bias. High-quality randomized trials or target trial emulation studies are needed before recommending widespread adoption, as certainty of evidence was very low across all outcomes.
- 2 September 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (6) , 806-814
Demographic and regional analysis of 22 years of mortality data from coexisting asthma and cardiovascular disease in the United States
Asthma and cardiovascular disease (CVD) are major health burdens with potential interconnections. This study analyzed mortality trends and demographic and regional disparities in US adults with coexisting asthma and CVD from 1999 to 2020. Using CDC WONDER data, we examined death certificates for individuals aged ≥25 years who died from 1999 to 2020 with both CVD (ICD I00–I99) and asthma (ICD J45–46). Age-adjusted mortality rates (AAMRs) and annual percent change (APC) were calculated by year, sex, age, race/ethnicity, region, and urbanization. There were 145,404 deaths involving both asthma and CVD. AAMR rose from 3.5 to 4.6 per 100,000, with a sharp increase from 2018 to 2020 (APC: 28.5; 95% CI: 17.34–35.05). Older adults had the highest AAMR (10.2). Women had higher rates than men (3.5 vs 2.4). Non-Hispanic (NH) Blacks had the highest AAMR (6.1), followed by NH American Indian/Alaska Natives (3.8), NH Asian/Pacific Islanders (3.5), Hispanics (3.0), and NH Whites (2.7). The Western region had the highest AAMR (3.7). Rates were similar across urban and rural areas. Mortality from coexisting asthma and CVD increased, especially among older adults, women, and NH Black individuals. Targeted public health strategies are needed to address these disparities.
- 2 September 2025
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 38 (6) , 806-814
Demographic and regional analysis of 22 years of mortality data from coexisting asthma and cardiovascular disease in the United States
Asthma and cardiovascular disease (CVD) are major health burdens with potential interconnections. This study analyzed mortality trends and demographic and regional disparities in US adults with coexisting asthma and CVD from 1999 to 2020. Using CDC WONDER data, we examined death certificates for individuals aged ≥25 years who died from 1999 to 2020 with both CVD (ICD I00–I99) and asthma (ICD J45–46). Age-adjusted mortality rates (AAMRs) and annual percent change (APC) were calculated by year, sex, age, race/ethnicity, region, and urbanization. There were 145,404 deaths involving both asthma and CVD. AAMR rose from 3.5 to 4.6 per 100,000, with a sharp increase from 2018 to 2020 (APC: 28.5; 95% CI: 17.34–35.05). Older adults had the highest AAMR (10.2). Women had higher rates than men (3.5 vs 2.4). Non-Hispanic (NH) Blacks had the highest AAMR (6.1), followed by NH American Indian/Alaska Natives (3.8), NH Asian/Pacific Islanders (3.5), Hispanics (3.0), and NH Whites (2.7). The Western region had the highest AAMR (3.7). Rates were similar across urban and rural areas. Mortality from coexisting asthma and CVD increased, especially among older adults, women, and NH Black individuals. Targeted public health strategies are needed to address these disparities.
- Open Access
- 7 August 2025
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 10 (1) , e78001
Trends in Mortality From Co-Occurring Diabetes Mellitus and Pneumonia in the United States (1999-2022): Retrospective Analysis of the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) Database
Background: Pneumonia is the most common respiratory tract infection among patients with diabetes, affecting individuals across all age groups and sexes. Objective: This study aims to examine demographic trends in mortality among patients diagnosed with both diabetes mellitus (DM) and pneumonia. Methods: Deidentified death certificate data for DM- and pneumonia-related deaths in adults aged 25 years and older from 1999 to 2022 were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated. The Joinpoint Regression Program was used to evaluate annual percentage changes (APCs) in mortality trends, with statistical significance set at P<.05. This study adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting. Results: Between 1999 and 2022, a total of 425,777 deaths were recorded from DM and pneumonia. The overall AAMR declined significantly (P=.001) from 98.73 in 1999 to 49.17 in 2016 (APC –4.68), and then surged to 97.66 by 2022 (APC 23.55). Men consistently experienced higher mortality than women throughout the study period. Male AAMR rose from 62.61 in 2016 to 127.05 in 2022 (APC 24.88), while female AAMR increased from 41.05 in 2017 to 75.25 in 2022 (APC 27.60). Race-based analysis demonstrated that American Indian or Alaska Native populations had the highest mortality rates among racial groups. Non-Hispanic White individuals exhibited a significant decline in AAMR (P=.002) from 89.76 in 1999 to 44.19 in 2017 (APC −4.58), followed by an increase to 83.11 by 2022 (APC 25.25). Adults aged 65 years or older bore the highest mortality burden, with rates declining steadily to 206.9 in 2017 (APC –5.15) before rising sharply to 371.3 in 2022 (APC 20.01). Nonmetropolitan areas consistently exhibited higher mortality than metropolitan areas, with particularly steep increases after 2018 (APC 64.42). Type-specific mortality revealed that type 1 DM AAMRs declined from 9.2 in 1999 to 1.4 in 2015 (APC –11.94) before rising again. By contrast, type 2 DM AAMRs surged drastically after 2017, peaking at 62.2 in 2020 (APC 58.74) before partially declining to 41.6 by 2022. Conclusions: DM is associated with an increased risk of mortality following pneumonia, particularly among men, older adults, and American Indian populations. Strengthening health care interventions and policies is essential to curb the rising mortality trend in these at-risk groups.
- 7 August 2025
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 10 (1) , e78001
Open AccessTrends in Mortality From Co-Occurring Diabetes Mellitus and Pneumonia in the United States (1999-2022): Retrospective Analysis of the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) Database
Background: Pneumonia is the most common respiratory tract infection among patients with diabetes, affecting individuals across all age groups and sexes. Objective: This study aims to examine demographic trends in mortality among patients diagnosed with both diabetes mellitus (DM) and pneumonia. Methods: Deidentified death certificate data for DM- and pneumonia-related deaths in adults aged 25 years and older from 1999 to 2022 were obtained from the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research (CDC WONDER) database. Age-adjusted mortality rates (AAMRs) per 1,000,000 population were calculated. The Joinpoint Regression Program was used to evaluate annual percentage changes (APCs) in mortality trends, with statistical significance set at P<.05. This study adhered to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for reporting. Results: Between 1999 and 2022, a total of 425,777 deaths were recorded from DM and pneumonia. The overall AAMR declined significantly (P=.001) from 98.73 in 1999 to 49.17 in 2016 (APC –4.68), and then surged to 97.66 by 2022 (APC 23.55). Men consistently experienced higher mortality than women throughout the study period. Male AAMR rose from 62.61 in 2016 to 127.05 in 2022 (APC 24.88), while female AAMR increased from 41.05 in 2017 to 75.25 in 2022 (APC 27.60). Race-based analysis demonstrated that American Indian or Alaska Native populations had the highest mortality rates among racial groups. Non-Hispanic White individuals exhibited a significant decline in AAMR (P=.002) from 89.76 in 1999 to 44.19 in 2017 (APC −4.58), followed by an increase to 83.11 by 2022 (APC 25.25). Adults aged 65 years or older bore the highest mortality burden, with rates declining steadily to 206.9 in 2017 (APC –5.15) before rising sharply to 371.3 in 2022 (APC 20.01). Nonmetropolitan areas consistently exhibited higher mortality than metropolitan areas, with particularly steep increases after 2018 (APC 64.42). Type-specific mortality revealed that type 1 DM AAMRs declined from 9.2 in 1999 to 1.4 in 2015 (APC –11.94) before rising again. By contrast, type 2 DM AAMRs surged drastically after 2017, peaking at 62.2 in 2020 (APC 58.74) before partially declining to 41.6 by 2022. Conclusions: DM is associated with an increased risk of mortality following pneumonia, particularly among men, older adults, and American Indian populations. Strengthening health care interventions and policies is essential to curb the rising mortality trend in these at-risk groups.
- Open Access
- 27 April 2025
- Published by Elsevier in Health Sciences Review
- Vol. 15
"Extrachromosomal circular DNA (eccDNA): A key driver of tumorigenesis, drug resistance, and prognosis across gastrointestinal malignancies”
- 27 April 2025
- Published by Elsevier in Health Sciences Review
- Vol. 15
Open Access"Extrachromosomal circular DNA (eccDNA): A key driver of tumorigenesis, drug resistance, and prognosis across gastrointestinal malignancies”
- 11 April 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 186, 235-243
Depression leading to suicide in United States: A retrospective analysis of CDC WONDER from 1999 to 2022
- 11 April 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 186, 235-243
Depression leading to suicide in United States: A retrospective analysis of CDC WONDER from 1999 to 2022
- 11 April 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (4) , e70216
Investigating the Therapeutic Potential of Tocilizumab Monotherapy in Isolated Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
- 11 April 2025
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 28 (4) , e70216
Investigating the Therapeutic Potential of Tocilizumab Monotherapy in Isolated Polymyalgia Rheumatica: A Systematic Review and Meta‐Analysis
- 25 March 2025
- Published by SAGE Publications in Nutrition and Health
- Vol. 31 (3) , 837-839
Chlormequat in our food: A potential hidden threat to health, highlighting the need for improved food safety practices
Background: Chlormequat (chlorocholine) is one of the most widely used plant growth regulators. It enhances the strength of cereal crops such as wheat and barley. The U.S. Environmental Protection Agency approved the use of chlormequat; however, in recent times, there has been growing concern about its health impacts, including endocrine and reproductive toxicity. Recent studies have highlighted the growing presence of chlormequat in food and biological samples, raising questions about long-term human exposure. Aim: This article highlights the critical need to review the safety issues associated with chlormequat use in food production by assessing its potential health risks and addressing existing regulatory inadequacies. By identifying gaps in current regulations and emphasizing the importance of consumer education, the article advocates for stronger food safety practices and more sustainable farming methods to reduce exposure to chlormequat. Implementing these solutions will not only mitigate potential health risks but also promote public health and improve overall food safety standards. Methods: Not applicable. Results: Observations have shown a steady and sharp rise in the level of chlormequat detection in both food and human biological samples over these years. Animal studies have confirmed significant disturbance in reproductive and endocrine functions, although studies in humans are scant. Current regulations do not include long-term human safety, though these regulations do set limits on residues. Furthermore, improper agricultural application increases the risks of overexposure. Conclusion: The result shows the implication of heightened regulatory measures, consumer awareness, and further research into the long-term effects of chlormequat on human health. Some concerns with chemical growth regulators like chlormequat could be minimized by promoting sustainable farming and precision agriculture methods.
- 25 March 2025
- Published by SAGE Publications in Nutrition and Health
- Vol. 31 (3) , 837-839
Chlormequat in our food: A potential hidden threat to health, highlighting the need for improved food safety practices
Background: Chlormequat (chlorocholine) is one of the most widely used plant growth regulators. It enhances the strength of cereal crops such as wheat and barley. The U.S. Environmental Protection Agency approved the use of chlormequat; however, in recent times, there has been growing concern about its health impacts, including endocrine and reproductive toxicity. Recent studies have highlighted the growing presence of chlormequat in food and biological samples, raising questions about long-term human exposure. Aim: This article highlights the critical need to review the safety issues associated with chlormequat use in food production by assessing its potential health risks and addressing existing regulatory inadequacies. By identifying gaps in current regulations and emphasizing the importance of consumer education, the article advocates for stronger food safety practices and more sustainable farming methods to reduce exposure to chlormequat. Implementing these solutions will not only mitigate potential health risks but also promote public health and improve overall food safety standards. Methods: Not applicable. Results: Observations have shown a steady and sharp rise in the level of chlormequat detection in both food and human biological samples over these years. Animal studies have confirmed significant disturbance in reproductive and endocrine functions, although studies in humans are scant. Current regulations do not include long-term human safety, though these regulations do set limits on residues. Furthermore, improper agricultural application increases the risks of overexposure. Conclusion: The result shows the implication of heightened regulatory measures, consumer awareness, and further research into the long-term effects of chlormequat on human health. Some concerns with chemical growth regulators like chlormequat could be minimized by promoting sustainable farming and precision agriculture methods.
- Open Access
- 25 February 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (2) , 229-238
Role of emerging theranostic technologies in precision oncology: revolutionizing cancer diagnosis and treatment
Theranostics is a technique used in precision oncology to combine focused treatments with diagnostic imaging, thereby enabling tailored cancer treatment. Using modern imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), Theranostics guarantees accurate tumor diagnosis and tailored treatment planning. Radiopharmaceuticals, such as Lutetium-177 (Lu-177) and prostate-specific membrane antigen (PSMA)-targeted therapies, have demonstrated significant clinical enhancements in progression-free and overall survival rates relative to traditional treatments, especially in prostate cancer and neuroendocrine tumors. Emerging technologies such as nanotheranostics and artificial intelligence (AI)-driven tools are enhancing the precision and efficacy of these treatments. However, the widespread application of theranostics is impeded by tumor heterogeneity, elevated prices, and restricted accessibility. Increased research and funding are necessary to address these issues and fully actualize theranostics’ potential to revolutionize cancer detection and therapy. To highlight the above challenges, this review examines diagnostic imaging and therapy advancements, focusing on clinical applications and technologies such as nanotechnology and AI-driven methods.
- 25 February 2025
- Published by Walter de Gruyter GmbH in Oncologie
- Vol. 27 (2) , 229-238
Open AccessRole of emerging theranostic technologies in precision oncology: revolutionizing cancer diagnosis and treatment
Theranostics is a technique used in precision oncology to combine focused treatments with diagnostic imaging, thereby enabling tailored cancer treatment. Using modern imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), Theranostics guarantees accurate tumor diagnosis and tailored treatment planning. Radiopharmaceuticals, such as Lutetium-177 (Lu-177) and prostate-specific membrane antigen (PSMA)-targeted therapies, have demonstrated significant clinical enhancements in progression-free and overall survival rates relative to traditional treatments, especially in prostate cancer and neuroendocrine tumors. Emerging technologies such as nanotheranostics and artificial intelligence (AI)-driven tools are enhancing the precision and efficacy of these treatments. However, the widespread application of theranostics is impeded by tumor heterogeneity, elevated prices, and restricted accessibility. Increased research and funding are necessary to address these issues and fully actualize theranostics’ potential to revolutionize cancer detection and therapy. To highlight the above challenges, this review examines diagnostic imaging and therapy advancements, focusing on clinical applications and technologies such as nanotechnology and AI-driven methods.